(EMAILWIRE.COM, February 07, 2019 ) According to the new market research report "Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

Don’t miss out on business opportunities in Immunohistochemistry Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=121632939

The global immunohistochemistry market is expected to reach USD 2.12 Billion by 2021 from USD 1.48 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021

The immunohistochemistry market is projected to reach USD 2.12 Billion by 2021, at a CAGR of 7.3% during the forecast period. Rising geriatric population, growing prevalence of chronic diseases, increasing number of diagnostic centers, and increasing physician awareness & demand for histopathology are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine offer significant growth opportunities in the market.

Immunohistochemistry (IHC) is a laboratory test that uses antibodies to test certain antigens in a tissue combining immunological, anatomical, and biochemical techniques. There are multiple approaches and permutation in immunohistochemistry applicable in drug testing and diagnosis of chronic diseases like cancer, infectious diseases, cardiovascular diseases, diabetes, and autoimmune diseases. The market covers the market size from 2014 to 2021.

Browse and in-depth TOC on " Immunohistochemistry Market"
181 – Tables
44 - Figures
225 - Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/immunohistochemistry-market-121632939.html

The immunohistochemistry market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period. Rising geriatric population, growing prevalence of chronic diseases, rapid technological developments in the IVD industry, and increasing healthcare spending are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine are expected to offer significant growth opportunities for players in the market. Regulatory restrictions in developed countries, however, are a major challenge faced by market players in the current market.

Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939

North America accounted for the largest share of the global immunohistochemistry market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Growth in the developed markets like North America and Europe is mainly driven by well-established healthcare industry, easy accessibility to advanced technologies, and growing opportunities for advanced cancer diagnostic testing and cancer screening. The demand in the APAC market is primarily driven by rising number of chronic diseases, rising standard of living, growing demand for quality medical care, increasing healthcare spending and government initiatives, and rising awareness on the use of immunohistochemistry tests.

Key Players:
The major players in the immunohistochemistry market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abcam plc (U.K.), Cell Signaling Technology, Inc. (U.S.), and Bio SB Inc. (U.S.).